- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 133 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 134 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- November 2022
- 154 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- June 2020
- 753 Pages
Global
From €3003EUR$3,300USD£2,575GBP
- Report
- January 2022
- 148 Pages
Global
From €3868EUR$4,250USD£3,316GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €455EUR$500USD£390GBP
- Report
- February 2024
- 117 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Book
- April 2020
- 320 Pages
- Book
- July 2018
- 360 Pages
Thalidomide is a drug used in the treatment of oncology, primarily multiple myeloma. It is an immunomodulatory agent, meaning it modulates the immune system to help fight cancer. It is also used to treat other conditions such as leprosy and erythema nodosum leprosum. Thalidomide is usually taken orally, but can also be administered intravenously. It is often used in combination with other drugs, such as corticosteroids, to increase its effectiveness.
Thalidomide has been used in oncology for over 50 years, and is still used today. It is generally well-tolerated, with few side effects. However, it can cause serious birth defects if taken during pregnancy, so it is important to use contraception when taking the drug.
The thalidomide market is highly competitive, with many companies offering the drug. Some of the major players in the market include Celgene, Teva Pharmaceuticals, and Mylan. Other companies include Sun Pharmaceuticals, Dr. Reddy's Laboratories, and Natco Pharma. Show Less Read more